Pancreactic Cancer: Succesful Trial against Pancreatic Cancer with Defence’s Arm-002 Anti-cancer Vaccine

Defence Therapeutics, Inc. announce the completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer. The vaccine was shown to be therapeutically effective against pre-established pancreatic cancer especially when combined with the anti-PD-1 immune-checkpoint inhibitor.